MARKET

BRTX

BRTX

Biorestorative Therapies Inc
NASDAQ
1.390
+0.080
+6.11%
Pre Market: 1.310 -0.08 -5.76% 09:14 04/18 EDT
OPEN
1.240
PREV CLOSE
1.310
HIGH
1.440
LOW
1.230
VOLUME
11.26K
TURNOVER
0
52 WEEK HIGH
7.13
52 WEEK LOW
1.200
MARKET CAP
9.41M
P/E (TTM)
-0.4068
1D
5D
1M
3M
1Y
5Y
Optimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic Advances
TipRanks · 17h ago
BIORESTORATIVE THERAPIES INC <BRTX.O>: MAXIM GROUP CUTS TARGET PRICE TO $6 FROM $10
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-WiSA Technologies, Rivian Automotive, Cigna Group
The Nasdaq and the S&P 500 were muted on Tuesday as higher Treasury yields pressured equities. The blue-chip Dow bucked the trend on robust results from health insurance heavyweight UnitedHealth. The Dow Jones Industrial Average was up 0.13% at 37,783.35. UnitedHealth Group's quarterly results beat expectations.
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals
Dow Jones Industrial Average up 0.13% after upbeat results from health insurer UnitedHealth. Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals among top stocks on the move. Higher Treasury yields and conflict in the Middle East keep investors on edge.
Reuters · 1d ago
BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment
BioRestorative Therapies shares were up 17% to $1.55. The company says FDA has cleared an amendment to the protocol of a Phase 2 study of BRTX-100 for treating chronic lumbar disc disease. The protocol amendment removes saline injection in the study and replaces it with a sham injection.
Dow Jones · 1d ago
BioRestorative gains as FDA clears amendment to study on cell therapy candidate
BioRestorative Therapies shares rose +15.91% to $1.53. FDA clears amendment to study on cell therapy candidate for chronic lumbar disc disease. The company's shares rose as much as 15.9%. The company says the study will now use a sham injection to treat the disease.
Seeking Alpha · 1d ago
BIORESTORATIVE THERAPIES SHARES UP 9.5% AFTER U.S. FDA CLEARS CHANGE TO CELL THERAPY'S MID-STAGE STUDY
Reuters · 1d ago
BUZZ-BioRestorative Therapies up as FDA clears change to study on cell therapy
BioRestorative Therapies shares rise 15.2% to $1.52 premarket. FDA clears change to study on cell therapy for chronic lumbar disc disease. Company says amendment replaces saline injection in the placebo group with a sham injection. Stock down 24% YTD.
Reuters · 1d ago
More
About BRTX
BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.

Webull offers BioRestorative Therapies Inc stock information, including NASDAQ: BRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BRTX stock methods without spending real money on the virtual paper trading platform.